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Simple Summary: There are currently no effective specific biomarkers for the screening of early 
gastric cancer. Recently, metabolomics has been used to profile small endogenous metabolites, 
demonstrating significant potential in the diagnosis/screening of cancer, owing to its ability to 
conduct a noninvasive sample analysis. Here, we performed a urine metabolomics analysis in the 
context of an early diagnosis of gastric cancer. This approach showed very high diagnostic 
sensitivity and specificity and performed significantly better than the analysis of serum tumor 
markers modalities. An additional genomic data analysis revealed the up-regulation of several 
genes in gastric cancer. This metabolomics-based early diagnosis approach may have the potential 
for mass screening an average-risk population and may facilitate endoscopic examination through 
risk stratification. 
Abstract: The early detection of gastric cancer (GC) could decrease its incidence and mortality. 
However, there are currently no accurate noninvasive markers for GC screening. Therefore, we 
developed a noninvasive diagnostic approach, employing urine nuclear magnetic resonance (NMR) 
metabolomics, to discover putative metabolic markers associated with GC. Changes in urine 
metabolite levels during oncogenesis were evaluated using samples from 103 patients with GC and 
100 age- and sex-matched healthy controls. Approximately 70% of the patients with GC (n = 69) had 
stage I GC, with the majority (n = 56) having intramucosal cancer. A multivariate statistical analysis 
of the urine NMR data well discriminated between the patient and control groups and revealed nine 
metabolites, including alanine, citrate, creatine, creatinine, glycerol, hippurate, phenylalanine, 
taurine, and 3-hydroxybutyrate, that contributed to the difference. A diagnostic performance test 
with a separate validation set exhibited a sensitivity and specificity of more than 90%, even with the 
intramucosal cancer samples only. In conclusion, the NMR-based urine metabolomics approach 
may have potential as a convenient screening method for the early detection of GC and may 
facilitate consequent endoscopic examination through risk stratification. 
Keywords: gastric cancer; screening; metabolomics; urine 
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1. Introduction 
Gastric cancer (GC) is the sixth most common type of cancer and the second leading cause of 
cancer-related mortality worldwide [1]. The overall survival and prognosis greatly depend on the 
disease stage, and the mortality from GC is mainly due to late presentation [2,3]. Therefore, early 
detection is critically important for reducing GC morbidity and mortality [4]. Further, early diagnosis 
is highly associated with a good prognosis [5–7]. Among screening methods for the early detection 
of GC, endoscopy is the most common modality [8]. However, endoscopy may be accompanied by 
complications, requires adequately qualified facilities, and is time-consuming [9–14]. 
The development of GC involves multiple genes and other factors, and tumors consist of mixed 
tissues and display various degrees of differentiation. There are currently no effective specific 
biomarkers for GC. Serum tumor markers are not satisfactory, mainly because of their poor 
diagnostic sensitivities. The sensitivities of Cancer embryonic antigen (CEA), CA 19-9, and CA 72-4 
are <20% for an early stage and 20–50% for advanced stages of cancer [15–18]. Several studies have 
attempted to improve the diagnostic value of these markers by combining more than two markers or 
using adjusted cutoff values [19–22]. However, these markers remain unsatisfactory for GC 
diagnosis, especially at early stages. Currently, several biomarkers have been proposed for GC, 
including GLS/GGCT protein coexpression levels in tissue samples and circulating miR21 in serum 
samples [23,24]. Although these invasive methods have shown very satisfactory results with high 
sensitivities and specificities, it is still necessary to develop a reliable screening tool for the early 
detection of GC that is sensitive, specific, and easy to use; moreover, a mostly noninvasive approach 
is highly desired. 
Metabolomics is used to profile small endogenous metabolites and has, in particular, 
demonstrated a significant potential in the diagnosis or screening of cancer, owing to its ability to 
noninvasively analyze samples [25–29]. Urine is arguably the most suitable sample because it is easy 
to obtain and can reflect the systemic metabolic status. Recently, urine metabolomics has been applied 
to the diagnosis of GC, with promising results [30–34]. A capillary electrophoresis-mass spectrometry 
(CE-MS)-based feasibility study by Chen et al. [30] used moving reaction boundary (MRB)-CE-MS 
for a better sensitivity and stability with a small number of samples. A nuclear magnetic resonance 
(NMR)-based metabolomics study [31] for early-stage GC diagnosis has also been reported; however, 
the study had multiple purposes, including the evaluation of curative surgery. Although the data 
showed great discrimination between groups based on urine sample analysis, the majority of the 
patient population had later than stage II GC. In other studies, the numbers of urine samples from 
patients with cancer and healthy controls were small (≤50), which could have limited the reliability 
of the studies. In addition, these studies included very limited numbers of cases of early GC, which 
is critical for GC screening [32–34]. Therefore, the actual diagnostic sensitivity and specificity for early 
GC detection by urine metabolomics have not been properly assessed. 
In this study, we performed a urine metabolomics analysis for GC diagnosis, with a particular 
focus on early GC. The diagnostic performance of the metabolomics approach was evaluated with a 
rigorous cross-validation using a separate validation set. A relationship between metabolic 
contributors and the gene expression profile in cancer tissues was also studied. 
2. Results 
2.1. Subject Characteristics 
The clinical information of the patients with GC and healthy subjects included in this study is 
detailed in Table 1. There were no significant differences in the demographic and laboratory findings 
between the two groups. The patients with GC were classified according to TNM (TUMOR-NODE-
METASTASIS) staging as follows: stage I, 69 patients; stage II, 10 patients; stage III, 15 patients; stage 
IV, 9 patients. Thus, this study population included many more patients with stage I, particularly IA, 
than later-stage patients. There were 55 cases with differentiated and 48 cases with undifferentiated 
cancer. Lymph node metastases were found in 22 (21.4%) cases. The proportions of abnormal 
conventional serum tumor markers are also shown in Table 1. 
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Table 1. Clinicopathologic characteristics of the study participants. 
Variables Whole Training Set Whole Validation Set 
 Gastric Cancer 
(n = 69) 
Control 
(n = 67) 
p-Value 
Gastric Cancer 
(n = 34) 
Control 
(n = 33) 
p-Value 
Age (years), mean (SD)  53.3 ± 11.1 54.9 ± 11.8 0.447 54.1 ± 9.1 55.4 ± 10.2 0.519 
Gender, male (%)  68.1 71.6 0.654 58.8 66.7 0.507 
BMI, mean (SD)  22.7 ± 3.2 23.1 ± 4.2 0.528 22.1 ± 3.9 22.8 ± 5.5 0.621 
Helicobacter pylori infection, n (%)       
Infected 22 (31.9) 22 (32.8) 0.716 13 (38.2) 11 (33.3) 0.897 
Uninfected 15 (21.7) 18 (26.9)  7 (20.6) 8 (24.2)  
Not examined 32 (46.4) 27 (40.3)  14 (41.2) 14 (42.4)  
Smoker, n (%)       
Current smoker 16 (23.2) 15 (22.4) 0.956 6 (17.6) 7 (21.2) 0.506 
Past smoker 15 (21.7) 16 (23.9)  5 (14.7) 8 (24.2)  
Nonsmoker 38 (55.1) 36 (53.7)  23 (67.6) 18 (54.5)  
Alcoholics, n (%)       
Heavy alcoholics 12 (17.4) 10 (14.9) 0.696 6 (17.6) 5 (15.2) 0.783 
Social drinker 57 (82.6) 57 (85.1)  28 (82.4) 28 (84.8)  
Laboratory finding       
Fasting blood glucose (mg/dL) 102 ± 6 100 ± 11 0.767 103 ± 8 102 ± 2 0.551 
Total cholesterol (mg/dL) 161 ± 22 156 ± 32 0.614 162 ± 11 151 ± 17 0.324 
AST (U/L) 27 ± 9 26 ± 2 0.522 26 ± 8 28 ± 8 0.483 
ALT (U/L) 19 ± 3 20 ± 4 0.559 17 ± 18 21 ± 3 0.427 
ALP (U/L) 74 ± 15 70 ± 12 0.311 73 ± 9 72 ± 2 0.652 
Total bilirubin (mg/dL) 0.7 ± 0.6 0.5 ± 0.3 0.682 0.8 ± 0.1 0.6 ± 0.4 0.531 
BUN (mg/dL) 14.1 ± 3.1 13.5 ± 3.7 0.747 14.3 ± 2.6 13.1 ± 5.9 0.829 
Creatinine (mg/dL) 1.07 ± 0.8 0.97 ± 0.4 0.299 1.09 ± 0.5 0.98 ± 0.9 0.185 
Uric acid (mg/dL) 5.2 ± 1.6 5.0 ± 1.5 0.688 4.9 ± 1.9 4.9 ± 2.1 0.759 
Blood pressure       
Systolic 130 ± 16 126 ± 15 0.738 126 ± 19 123 ± 21 0.717 
Diastolic 73 ± 12 74 ± 7 0.580 75 ± 18 72 ± 15 0.392 
TNM stage a   - -  - - 
I (IA/IB) 46 (37/9)   23 (19/4)   
II (IIA/IIB)  7 (5/2)   3 (2/1)   
III 10   5   
IV 6   3   
Cancers 2020, 12, 2904 4 of 16 
Presence of lymph node metastasis, n (%)  15 (21.7) - - 7 (20.6) - - 
Histologic diagnosis, n (%)  - -  - - 
Differentiated 37 (53.6)   18 (52.9)   
Undifferentiated 32 (46.4)   16 (47.1)   
Epstein–Barr virus positivity, n (%) 8 (11.6)   4 (11.8)   
Serum tumor marker  
(>cutoff value/total)  
  -   - 
CA 19-9 b  3 (4.3) 1 (1.5) 0.324 1 (2.9) 0 0.321 
CEA c 2 (2.9) 1 (1.5) 0.577 0 0 - 
CA 72-4 d 6 (8.7) 2 (3.0) 0.157 2 (5.9) 1 (3.0) 0.573 
a According to the American Joint Committee on Cancer Staging Manual (7th edition); b Cutoff value of >37 U/mL; c Cutoff value of >7 ng/mL; d Cutoff value of >4 U/mL. 
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2.2. Study Design 
To evaluate the performance of the diagnostic model, validation was carried out with a separate 
validation set, as previously described [35]. Briefly, we randomly selected one-third of the samples 
from each group (within the cohorts) as the validation set (34 of 103 for the GC group and 33 of 100 
for the healthy control group). The remaining samples (training set) were used to develop the 
diagnostic model. Similarly, in the analysis of the diagnostic performance of the three subgroups—
stage IA cohort, stage I (IA+IB) cohort, and stage I+II cohort—one-third and two-thirds of the samples 
from each cohort were selected as the validation and training sets, respectively. These datasets from 
all cohorts were balanced for age, sex, Helicobacter infection, and other clinical characteristics (Table 
1). 
2.3. Discrimination between Urine Samples from Healthy Subjects and Patients with GC Using NMR 
Spectra 
All urine metabolic profiles, from both patients with GC and healthy controls, were obtained 
using NMR spectroscopy. Representative spectra from both groups were similar, but there were 
differences in specific regions, indicating subtle metabolic differences (Figure 1A). For a more holistic 
analysis of the NMR data for a training set, we performed a multivariate statistical analysis and 
established an orthogonal projection for a latent structure-discriminant analysis (OPLS-DA) model. 
The OPLS-DA approach is a method for the classification of groups with confounding factors, such 
as multicollinear and noisy variables [36]. The discrimination model was built with one predictive 
and two orthogonal components, and it exhibited an R2(Y) (overall goodness of fit) of 86.5% and Q2(Y) 
(overall cross-validation coefficient) of 72.8% (Figure 1B). Most of the samples in the prediction set 
were clustered into the corresponding groups, and only a few samples overlapped across the groups. 
In addition, a partial least squares-discriminant analysis (PLS-DA) score plot showed that there were 
no significant differences between the healthy subjects and GC patients at any stage based on 
Helicobacter pylori infection (Figure S1). 
 
Figure 1. Representative 1H nuclear magnetic resonance (NMR) spectra of urine samples and 
discrimination between healthy control and gastric cancer groups. (A) Typical 1H NMR spectra with 
an internal standard signal (0.025% TSP) at 0 ppm. The left panel shows a representative 1H NMR 
spectrum for healthy controls, and the right panel shows a representative 1H NMR spectrum for 
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patients with gastric cancer. (B) Orthogonal projections to the orthogonal projection for a latent 
structure-discriminant analysis (OPLS-DA) score plot of the healthy control and gastric cancer 
groups. The model was constructed with one predictive (Pp) and two orthogonal (Po) components. 
The overall goodness of fit and cross-validation coefficients are 86.5 and 72.8%, respectively. Black 
boxes: samples from healthy controls; red triangles: samples from patients with gastric cancer. 
2.4. Analysis of Contributing Metabolites Using Statistical Total Correlation Spectroscopy (S-TOCSY) 
The identities of the metabolites that contributed to the difference between the cancer and 
healthy control groups were determined by assigning NMR peaks and performing a statistical 
analysis (Table 2, Figure S2). 
All metabolites with statistically meaningful differences were identified by matching their peak 
characteristics with those in databases and are shown in Figure 2A and Table S1. Of the identified 
metabolites, alanine, taurine, phenylalanine, and creatine have been previously described as urinary 
metabolomics markers for GC [31–33,37]. We observed low creatine and high creatinine levels in the 
urine from the normal subjects and, conversely, high creatine and low creatinine levels in the urine 
from the patients with GC (Figure 2B). The levels of these markers varied rather widely, with those 
of citrate showing the widest variation between the healthy control and cancer groups (Figure 2B). In 
addition, the fold increases were not very large, and thus it was difficult to find a single representative 
marker metabolite. As the (P corr) p-values of each signal in the S-TOCSY plot were also rather small 
(maximum value ≤0.7), multiple metabolites, rather than one or two major metabolites, seemed to 
intricately contribute to the group separation. Additionally, we performed a receiver operating 
characteristic (ROC) curve analysis, and the results showed a broad range of areas under the curves 
(AUCs), from 0.632 (citrate) to 0.936 (glycerol), with varying sensitivities and specificities (Figure 2C). 
The results of the ROC analysis are summarized in Table 2. 
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Figure 2. Identification of contributing metabolites by statistical total correlation spectroscopy, their 
relative levels in urine samples, and ROC analysis. (A) The color scale P(corr)p on the right represents 
a modeled correlation, and Pp represents a modeled covariation. The names are indicated for 
metabolites with noticeable signals, whose distribution was different between the healthy control and 
gastric cancer groups. (B) Relative concentrations of identified metabolites in urine samples from 
healthy controls and patients with gastric cancer and associated p-values. The shown false discovery 
rate (FDR)-adjusted p-values were acquired through the online statistical analysis tool Metaboanalyst 
(www.metaboanalyst.ca). (C) ROC curves of each identified metabolite, with area under the curve 
(AUC), sensitivity, and specificity. 
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Table 2. Identified metabolites, with changes in their levels in gastric cancer (GC) and receiver 
operating characteristic (ROC) analysis results. 










1 Alanine 1.49(d), 1.18 × 10−4 ▲ 0.748 70 80 
2 Citrate 2.54(d), 2.68(d) 1.60 × 10−4 ▲ 0.632 50 70 
3 Creatine 3.04(s) 1.90 × 10−9 ▲ 0.863 80 90 
4 Creatinine 3.05(s), 4.07(s) 3.27 × 10−5 ▽ 0.723 60 80 
5 Glycerol 3.57(m), 3.66(m), 3.78(m), 7.51 × 10−19 ▽ 0.936 90 90 
6 Hippurate 3.98(d), 7.55(t), 7.64(t), 7.83(m) 1.75 × 10−6 ▲ 0.74 70 70 
7 Phenylalanine 7.32(m), 7.38(m), 7.42(m) 1.13 × 10−8 ▲ 0.802 80 70 
8 Taurine 3.27(t), 3.43(t) 1.90 × 10−6 ▲ 0.759 80 70 
9 3-hydroxybutyrate 1.21(d) 4.61 × 10−4 ▽ 0.706 60 70 
▲ represents up-regulation and ▽ represents down-regulation. 
2.5. Diagnostic Performance: Validation of the Prediction Model 
We developed a prediction model that discriminated between cancer and healthy control 
samples using a training set. Therefore, we tested whether our model could predict the cancer status 
of unknown samples from the validation set, which were set aside during model building. 
NMR data of the validation set were obtained using the same experimental parameters as those 
used for the training set, and the data were fitted into the prediction model to obtain the cancer status 
using an a priori set cutoff value of 0.5 for the predicted dependent variable (Figure 3A). 
 
Figure 3. Prediction of healthy subjects and patients with gastric cancer using unknown samples and 
early-stage diagnosis. (A) For validation, 67 unknown samples (33 healthy control and 34 gastric 
cancer samples) were fitted into the OPLS-DA model. The class membership of the unknown samples 
was predicted using an a priori set cutoff value of 0.5 (dashed line). The Y-values of the black boxes 
and red triangles are from the analysis of known samples (67 healthy control and 68 gastric cancer 
samples), and gray triangles represent unknown samples. (B) For early-stage diagnosis, the gastric 
cancer group only comprised patients with stage IA cancer (n = 37), and the diagnostic model was 
established using the same healthy control group (n = 67). Validation was performed with 52 
unknown samples (gray triangles). Black boxes: samples from healthy controls; red triangles: samples 
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from patients with gastric cancer. In the case of misclassified samples, the predicted Y-values for 
unknown samples are shown as gray triangles. 
This validation test correctly predicted the respective status of 31 of 33 healthy control samples 
and 32 of 34 cancer samples, thus yielding a specificity of 93.9% and a sensitivity of 94.1% for the 
diagnosis of GC. Moreover, the sensitivity and specificity of CEA, CA19-9, and CA72-4 were 
determined (Table 3). Compared with the serum tumor markers for the same patients, the 
metabolomics approach performed significantly better, especially in terms of sensitivity. 
For early GC screening, it is desirable to have a diagnostic model that can perform well without 
the inclusion of later-stage samples. Therefore, we carried out a diagnostic performance test as above 
after excluding later-stage samples (Figure S3 and Table 3). The metabolomics approach showed a 
robust performance even with the earliest, stage IA samples (R2 > 0.508 and Q2 > 0.676) and exhibited 
a specificity of 97% (32 correct predictions for 33 healthy control samples) and a sensitivity of 94.7% 
(18 correct predictions for 19 cancer samples) (Figure 3B). 
Table 3. Comparison of sensitivity and specificity of conventional modalities and metabolomics 
profiling for early-stage and locally advanced gastric cancer. 
Variable 




I + II 
Stage 







Sensitivity (%) 93.9 90.9 97.0 97.0 1.9 3.9 7.8 
Specificity (%) 94.1 92.3 95.7 94.7 99.0 99.0 97.0 
2.6. Relationship between Urine Metabolites and Gene Expression in Cancer Tissues 
After confirming the utility of the proposed model in predicting early GC, we wanted to 
determine whether there was a relationship between the metabolic contributors and gene expression 
profiles in GC. Although one or two significant marker metabolites did not account for a large part 
of the metabolic alterations between the healthy control and cancer groups, a metabolic–genetic 
relationship might reveal a weak but significant correlation. To this end, we analyzed microarray 
data for patients with GC (n = 103) and normal controls (n = 29) and examined the expression levels 
of genes known to metabolize the identified contributing metabolites [38]. We applied the 
bioinformatics network visualization tool MetScape to perform a pathway-based network analysis 
[39]. The software allows the visualization and interpretation of metabolomics and gene expression 
datasets in a human metabolic network context. Using the compound–reaction–enzyme–gene 
analysis function of MetScape, we could obtain enzymes potentially related to the metabolites 
identified by our metabolomics analysis. In brief, we conducted a pathway analysis based on our 
metabolomics results to elucidate potentially related genes (Figure S4A). Subsequently, we analyzed 
the expression levels of the genes encoding these enzymes using the Chen’s microarray dataset and 
found significant changes in the expression of some genes (Figures S5,S6; Table S3). We performed a 
volcano plot analysis for selecting meaningful genes based on a fold change of 1.5 and a false 
discovery rate (FDR) of 0.005. As a result, we selected five genes including ACLY, ACO2, BAAT, 
CKMT1B, and GGTL4 (Figure S4B). A joint pathway analysis using the identified metabolites and 
correlated genes was also performed; overall, the result supports the abovementioned findings 
(Figure S4C). 
3. Discussion 
Metabolomics, which is used to assess the overall metabolic profiles of biological samples, may 
help establish the missing link between gene/protein expression profiles and final cellular 
phenotypes in normal and diseased states. Metabolomics urine analysis is also attractive for the 
routine monitoring of cancer because urine contains high concentrations of many water-soluble 
metabolites present in plasma and sampling is noninvasive. Several studies have shown that urine 
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metabolomics analysis provides a potential diagnostic tool for the early detection of cancer [27,40–
42]. 
To date, several studies have explored the utility of metabolomics in the diagnosis of GC. Early 
reports mostly used tissue samples obtained from surgery or endoscopic biopsies [37,43,44], aiming 
at directly detecting metabolic alterations in cancer tissues. However, studies that are more recent 
have obtained comparable results using more accessible samples such as blood or urine [31,34,45]. 
Important drawbacks of these studies were small numbers of cases and a lack of rigorous cross-
validation to assess the actual diagnostic performance of the metabolomics approach. The current 
study has thus far employed the largest number of cases. In addition, our validation set corresponded 
to one-third of all enrolled cases and was larger than those used in most of the previous studies. 
Therefore, the high diagnostic performance of our approach should be considered more reliable than 
that of previous studies. 
Clinically, another equally important aspect of our study was the inclusion of a large number of 
patients with stage I GC. Among the enrolled cases with cancer, more than half had stage I GC, 
including 56 cases with intramucosal cancer, which can be treated by endoscopic resection. In 
addition, we achieved a comparably high diagnostic performance using only intramucosal lesions. 
In comparison, a previous study that reported the diagnostic performance of metabolomics included 
no stage IA cases in the training set, although it included 13 stage IA cases in the validation set [31]. 
It should be also noted that conventional tumor markers performed very poorly, with a low 
sensitivity. The current study is the first noninvasive metabolomics diagnosis study that focused on 
early GC. 
Despite the high diagnostic performance, our approach could not establish a firm mechanistic 
link between metabolite changes and GC, nor could it identify a single marker metabolite that 
explained the metabolic difference between healthy controls and cases with GC. Nevertheless, this 
analysis can be performed quickly and affordably, provided a diagnostic facility is available, at a low 
cost and without the need for medically trained personnel. Therefore, the urine metabolomics 
approach should be suitable for early GC screening, rather than the confirmation of GC, which should 
be performed by expert pathologists. Combined with the convenience and noninvasive nature of 
urine analysis, this method should be applicable to the general population. 
Although we found several metabolites that contributed to the metabolic difference between 
patients with cancer and healthy controls, the correlations of these metabolites with differences 
between the groups were rather small. Interestingly, we found that the creatine and creatinine levels 
showed opposite trends in the normal controls and in patients with GC. Up to 94% of creatine is 
found in muscle tissues, and it is nonenzymatically converted to creatinine and excreted into urine 
through the kidney [46]. A significant correlation has been reported between creatine metabolism 
and muscle mass [47], which is helpful in interpreting the inverse relationship between the measured 
concentrations of these two metabolites in our study. Compared with that in normal controls, muscle 
mass is likely to be relatively deteriorated in patients with GC, which may lead to abnormal creatine 
metabolism. Based on these effects, the high levels of creatinine were interpreted to be due to the 
conversion of creatine to creatinine in the normal controls, while relatively low levels of creatinine 
were measured in the patients with GC. Creatine conversion to creatinine is a nonenzymatic reaction, 
which is potentially due to the failure to find specific enzymes associated with this reaction. 
Unfortunately, with insufficient metabolic data, a direct mechanistic investigation of GC was not 
possible in the current study. However, the diagnostic performance was evaluated using all the 
metabolite signals as a whole and was found to be much higher than that of conventional markers or 
a radiological approach. In fact, one advantage of the metabolomics approach is that no identification 
of a single significant marker is necessary for disease diagnosis, as noted previously [48]. In addition, 
it has been noted that the measured metabolite profile is a reflection of the convergence of tumor, 
microenvironment, and global metabolic alterations [49]. Therefore, finding one or two significant 
metabolites whose levels can account for a large part of metabolic differences between patients with 
cancer and normal cases seems to be very difficult, if possible. Actually, there are noticeable 
variations in the levels of contributing metabolites. These variations may reflect the well-known 
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heterogeneity of solid tumors. In a large-scale sequencing analysis of major human cancers, it was 
estimated that 3000 to 10,000 mutations could be found in one of the cancer genomes [50]. This 
heterogeneity may account for the difficulties in finding a single significant metabolite marker. 
Citrate, a metabolic intermediate of the tricarboxylic acid (TCA) cycle, has been previously 
identified as a GC biomarker [51], but there remain inconsistencies regarding its levels, with some 
studies reporting increases and others reporting decreases in citrate levels in GC [51,52]. These 
differences may indicate that the distribution range of citrate levels is quite large in GC, as was 
observed in our study. However, further qualified studies, including a controlled trial or a cohort 
study, should be conducted to validate the screening programs using urine metabolomics profiles. 
Although our metabolomics results showed different total metabolic profiles between healthy 
and GC patients, these results cannot stand alone. The complementation for functional linkage via 
the incorporation of other “omics” datasets in the context of system biology is always required. For 
this purpose, we conducted a pathway analysis using microarray data to disclose any potential 
correlation with our metabolomics results. Importantly, we found several metabolite-gene expression 
correlations. For instance, the expression of ACO2, an enzyme that plays a critical role in the catalysis 
of citrate to isocitratewas down-regulated in GC patients, supporting the increased citrate levels 
observed through our metabolomics analysis. Moreover, GGTL4, a member of gamma-
glutamyltransferase that plays a key role in the transfer of gamma-glutamyl functional groups to 
amino acids, expression levels were down-regulated in GC patients. Although a direct correlation 
between the GGTL4 levels and the production of alanine and taurine may be questionable, GGTL4 is 
located in a metabolic pathway close to those essential for the production of these metabolites. 
Another gene responsible for the catalysis of acyl-CoA thioester into either glycine or taurine, BAAT, 
was up-regulated in GC patients; again, this could be the reason for the elevated taurine levels in GC 
patients. We also found that mitochondrial creatine kinase (CKMT1B) was differentially expressed in 
GC patients. CKMT1B is responsible for the transfer of high-energy phosphate groups from the 
mitochondria to creatine. However, this gene is not directly involved in creatine production, making 
it difficult to determine the correlation between the expression of CKMT1B and the creatine levels in 
GC patients. Importantly, overall, we confirmed that the suggested metabolite-gene correlation was 
supported by the results of additional joint pathway analysis. 
In addition, the pepsinogen I/II ratio, which is recently coming into the spotlight, for identifying 
a high-risk GC group was not examined in this study. However, this biomarker is known to be a 
useful serologic marker for chronic atrophic gastritis, which is a precancerous lesion. Hence, the 
purpose of this marker is not consistent with this study as this study demonstrated the diagnostic 
performance of a metabolomics profile in the detection of GC regardless of accompanying atrophic 
or metaplastic change. Furthermore, as the sensitivity and specificity of the pepsinogen test differ 
from country to country, further research is required to increase the efficacy of pepsinogen as a GC 
biomarker [53]. Another issue is about change of metabolomics profile after treatment. In our study, 
we only compared active cancer patients and healthy subjects. The evaluation of the urine 
metabolomics profile of gastric cancer patients, after curative resection, should also be considered, 
even though there could be a confounding bias due to the dietary life change after surgical 
gastrectomy. This said, further studies are warranted to elucidate the metabolomics change in gastric 
cancer subjects, before and after surgery. 
For the NMR spectra normalization, we applied the “total area normalization approach”, a 
numerical normalization method rather than a physiological method using, e.g., the osmolality or 
creatinine levels. Indeed, the normalization against creatinine should be used when the creatinine 
clearance is constant under stable metabolic regulation. Of note, such an approach is not suitable for 
our study, because gastric cancer is one of the many diseases causing metabolic dysregulation. Even 
though the urinary specific gravity and osmolality measurements are currently recommended as 
normalization methods for the analysis of urine samples, these approaches require an additional 
measurement, a critical limitation in the context of high-throughput screening research. While 
various numerical normalization methods are proposed, each approach has its own advantages and 
limitations [54]. Therefore, the standardized normalization method for NMR-based urine 
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metabolomics has not been established. However, for large sample size-based studies (over 50 
samples), the quantile normalization has been suggested with better results, which we will consider 
as an additional option in further research. 
4. Materials and Methods 
4.1. Patients 
The study design was approved by the Institutional Review Board at the Samsung Medical 
Center (IRB No. 2012-08-045), and written informed consent was obtained from all subjects enrolled 
in this study. We collected urine samples from patients with GC (n = 103) and age- and sex-matched 
healthy subjects (n = 100) at the Samsung Medical Center. Patients with prior treatment, including 
chemotherapy or surgery, serious complications such as active bleeding or an obstruction, abnormal 
liver function or renal function test results, severe cardiopulmonary disease, collagen disease, 
uncontrolled diabetes mellitus, and active carcinoma at other sites were excluded. All patients were 
diagnosed using biopsy or surgical resection. Healthy controls were age- and sex-matched subjects 
with no declared history of any gastrointestinal or chronic diseases, and no gastrointestinal 
symptoms. Furthermore, healthy controls showed normal endoscopic findings, as per the endoscopic 
examination results. Subjects diagnosed with benign gastric diseases including gastritis, 
gastroesophageal reflux disease, ulcer, or benign tumors (as per the endoscopic examination results) 
were not included in this study. Control samples were obtained from healthy subjects who 
underwent a routine health check-up at the Samsung Medical Center in the same period. The 
selection criteria required individuals to not meet the above-listed exclusion criteria, including 
neoplasms. All subjects were instructed to fast for 8 h before the collection of urine samples. 
Participants provided a midstream urine sample. No dietary restriction or activity modification was 
required before the urine collection. 
4.2. Serum Assays of CEA, CA 19-9, and CA 72-4 
Blood samples were obtained from all patients in the morning during the week before surgery. 
The blood sample was centrifuged at 1000 × g for 10 min to separate the plasma from blood cells. 
Serum CEA, CA 19-9, and CA 72-4 were measured using a radioimmunoassay. The normal values of 
CEA, CA 19-9, and CA 72-4 were set at less than 7 ng/mL, 35 U/mL, and 4 U/mL, respectively. 
4.3. Urine Sample Collection and Preparation 
First morning urine samples (3–5 mL) were collected and centrifuged at 3000 rpm for 15 min at 
4 °C. The supernatants were transferred to frozen tubes and stored at −80 °C until processing. The 
frozen urine samples were gently thawed and centrifuged at 15,000 rpm for 20 min at 4 °C. A 500-µL 
aliquot of the supernatant was mixed with 50 µL of phosphate buffer (1.5 M K2HPO4, 1.5 M Na2HPO4, 
and pH 7.4), centrifuged at 15,000 rpm for 20 min at 4 °C, and then incubated at room temperature 
for 10 min. For the internal standard, 50 µL of a 0.25% trimethylsilylpropanoic acid (TSP) solution in 
D2O was added to 450 µL of a centrifuged supernatant, and the mixture was transferred into a 5-mm 
NMR tube. 
4.4. NMR Data Acquisition and Determination of Metabolic Profiles 
All 1H NMR spectra were obtained using a 500-MHz NMR spectrometer (BioSpin Avance 500; 
Bruker, Billerica, MA, USA), which was operated at a 500.13-MHz proton frequency at 25 °C using 
the Carr–Purell–Meiboom–Gill pulse sequence (cpmgpr1d) with 400 ms of the total spin echo delay. 
The acquisition parameters and data processing steps were as reported previously [35,55]. In brief, a 
proton spectral FID was collected within a 14-ppm spectral width during 128 scans. A Fourier 
transformation and phase correction were applied to proton NMR signals using the MNova software 
(Mestrelab Research S.L., Escondido, CA, USA). The water signal region (4.62–5.15 ppm) was 
excluded, and the data were normalized and referenced to the total area integration values and the 
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0.025% TSP value, respectively. All the processed data were compared against the Chenomx NMR 
database version 8.2 (Spectral Database, Edmonton, AB, Canada) to identify representative 
metabolites by shifting in appropriate pH ranges. To distinguish between the healthy controls and 
patients with GC, OPLS-DA was performed using SIMCA-P version 11.0 (Umetrics, Umeå, Sweden) 
by applying spectral binning data by using an in-house Perl script with a 0.0073-ppm width. To 
evaluate the performance of the OPLS-DA model, validation was carried out using a separate 
validation set. Briefly, one-third of the samples from each cohort were randomly selected and used 
as the validation set using the k-fold cross-validation method. The diagnostic performance of the 
OPLS-DA model was evaluated based on the Y-variable values of the validation set, obtained using 
the training set model with an a priori set cutoff value of 0.5. The sensitivity and specificity values 
were obtained based on the correct prediction of the 33 healthy control and 34 GC patient samples 
during the validation step. All statistical analyses were performed using statistical software and an 
online data analysis tool, including SIMCA-P version 11.0 (Umetrics, Umeå, Sweden), OriginPro 8 
(OriginLab Corporation, Northampton, MA, USA), R (The R Foundation for Statistical Computing, 
Vienna, Austria), and Metaboanalyst (www.metaboanalyst.ca). 
4.5. Microarray Data Analysis 
The variation of gene expression in human GC was investigated using the microarray results by 
Chen et al. [38] Genes involved in the metabolism of the contributing metabolites, identified by S-
TOCSY, and were investigated for their differential expression in cancer and normal samples. In 
detail, we performed pathway-based network analysis using MetScape to visualize and interpret 
metabolomics and gene expression data in the human metabolic network [39]. We used metabolites 
identified by our metabolomics analysis, and the pathway-based network was built using the 
compound–reaction–enzyme–gene method. Subsequently, we obtained the names of the genes 
potentially associated with the input metabolites and analyzed the gene expression levels from 
Chen’s microarray dataset [38]. From Chen’s research dataset, we downloaded all individual 
microarray data from normal control and patients, and generated a new summarized gene list 
consisting of “R/G Normalized (Mean)” value to determine the fold changes and adjusted p-values 
of each gene. 
5. Conclusion 
In conclusion, we report here a metabolomics approach for GC screening using urine samples 
from patients who were mostly diagnosed with early GC and healthy subjects. This approach showed 
very high diagnostic sensitivity and specificity using a validation set and performed significantly 
better than did serum tumor markers modalities. An additional genomic data analysis revealed an 
up-regulation of the expression of several genes in GC. As this was the largest metabolomics study 
and the first that mostly focused on early GC, the approach developed may have the potential for a 
mass screening of an average-risk population and may facilitate endoscopic examination through 
risk stratification. 
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